South Korea · Delayed Price · Currency is KRW Genolution Statistics
Total Valuation
Genolution has a market cap or net worth of KRW 24.72 billion. The enterprise value is 20.96 billion.
| Market Cap | 24.72B |
| Enterprise Value | 20.96B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genolution has 18.07 million shares outstanding. The number of shares has increased by 0.28% in one year.
| Current Share Class | 18.07M |
| Shares Outstanding | 18.07M |
| Shares Change (YoY) | +0.28% |
| Shares Change (QoQ) | -0.32% |
| Owned by Insiders (%) | 22.30% |
| Owned by Institutions (%) | n/a |
| Float | 13.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.46 |
| PB Ratio | 0.36 |
| P/TBV Ratio | 0.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.29, with a Debt / Equity ratio of 0.35.
| Current Ratio | 1.29 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | -7.31 |
| Interest Coverage | -8.98 |
Financial Efficiency
Return on equity (ROE) is -7.88% and return on invested capital (ROIC) is -11.37%.
| Return on Equity (ROE) | -7.88% |
| Return on Assets (ROA) | -4.76% |
| Return on Invested Capital (ROIC) | -11.37% |
| Return on Capital Employed (ROCE) | -10.75% |
| Weighted Average Cost of Capital (WACC) | 3.87% |
| Revenue Per Employee | 133.75M |
| Profits Per Employee | -62.14M |
| Employee Count | 75 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 2.19 |
Taxes
In the past 12 months, Genolution has paid 3.90 million in taxes.
| Income Tax | 3.90M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.59% in the last 52 weeks. The beta is 0.13, so Genolution's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -45.59% |
| 50-Day Moving Average | 1,333.62 |
| 200-Day Moving Average | 1,710.32 |
| Relative Strength Index (RSI) | 50.10 |
| Average Volume (20 Days) | 32,472 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genolution had revenue of KRW 10.03 billion and -4.66 billion in losses. Loss per share was -257.82.
| Revenue | 10.03B |
| Gross Profit | 3.10B |
| Operating Income | -7.44B |
| Pretax Income | -5.65B |
| Net Income | -4.66B |
| EBITDA | -5.78B |
| EBIT | -7.44B |
| Loss Per Share | -257.82 |
Balance Sheet
The company has 26.83 billion in cash and 24.03 billion in debt, with a net cash position of 2.80 billion or 155.07 per share.
| Cash & Cash Equivalents | 26.83B |
| Total Debt | 24.03B |
| Net Cash | 2.80B |
| Net Cash Per Share | 155.07 |
| Equity (Book Value) | 68.83B |
| Book Value Per Share | 3,870.04 |
| Working Capital | 7.30B |
Cash Flow
In the last 12 months, operating cash flow was -3.01 billion and capital expenditures -277.26 million, giving a free cash flow of -3.28 billion.
| Operating Cash Flow | -3.01B |
| Capital Expenditures | -277.26M |
| Depreciation & Amortization | 1.65B |
| Net Borrowing | -305.74M |
| Free Cash Flow | -3.28B |
| FCF Per Share | -181.82 |
Margins
Gross margin is 30.94%, with operating and profit margins of -74.15% and -46.46%.
| Gross Margin | 30.94% |
| Operating Margin | -74.15% |
| Pretax Margin | -56.28% |
| Profit Margin | -46.46% |
| EBITDA Margin | -57.67% |
| EBIT Margin | -74.15% |
| FCF Margin | n/a |
Dividends & Yields
Genolution does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.28% |
| Shareholder Yield | -0.28% |
| Earnings Yield | -18.86% |
| FCF Yield | -13.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 19, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Apr 19, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Genolution has an Altman Z-Score of 1.46 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.46 |
| Piotroski F-Score | 2 |